Urolithin A affects cellular migration and modulates matrix metalloproteinase expression in colorectal cancer cells

Area of Science:

• Gastroenterology
• Oncology
• Molecular Biology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer-related deaths globally.
• Preventing tumor cell proliferation and metastasis is crucial for improving patient survival in CRC.
• Polyphenols, including urolithin A (UA), exhibit potential anticancer properties.

Purpose of the Study:

• To investigate the effects of the gut-microbiota metabolite urolithin A (UA) on colon cancer cell lines.
• To evaluate UA's impact on cell proliferation, migration, and metastasis.
• To explore UA's potential as an adjuvant therapy for colorectal cancer.

Main Methods:

• Cellular assays were performed on multiple colon cancer cell lines treated with varying concentrations of UA.
• Wound-healing experiments assessed cell migration.
• Colony formation assays evaluated cell proliferation and survival.
• Western blot analysis was used to determine the expression levels of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).

Main Results:

• Urolithin A significantly suppressed colon cancer cell growth, migration, and colony formation in a dose- and time-dependent manner.
• UA treatment markedly reduced the expression of matrix metalloproteinases 1 and 2 (MMP1 and MMP2), key mediators of metastasis.
• UA significantly increased the expression of tissue inhibitor of metalloproteinases 1 (TIMP1), further inhibiting cellular metastasis.

Conclusions:

• Urolithin A demonstrates significant anticancer properties against colon cancer cells.
• UA effectively inhibits colon cancer cell migration and metastasis by modulating MMP and TIMP expression.
• These findings suggest that urolithin A holds promise as a therapeutic agent or adjuvant therapy for colorectal cancer.